In this issue:
Perioperative pembrolizumab for early-stage NSCLC
Perioperative nivolumab for stage III NSCLC
SABR + immunotherapy for stage IA–B or IIA–B NSCLC
Cemiplimab in advanced NSCLC with PD-L1 ≥50%
TTF for metastatic NSCLC
Tepotinib for METex14 NSCLC
Diabetes reduces pembrolizumab efficacy in NSCLC
Neoadjuvant osimertinib then RT and/or surgery in stage III EGFR-mutant NSCLC
Early relapse predictors in stage III NSCLC after consolidation durvalumab
Mortality in elderly NSCLC according to management strategy
Please login below to download this issue (PDF)